NCT07289464

A Clinical Study of RSS0343 in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RSS0343 Following Multiple Oral Doses in Healthy Subjects, as Well as Its Effects on the QT/QTc Interval

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Reistone Biopharma Company Limited · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.

Conditions

• Non-cystic Fibrosis Bronchiectasis

Interventions

Type	Name	Description
DRUG	RSS0343 Tablets	RSS0343 tablets, oral.
DRUG	RSS0343 Tablets Placebo	RSS0343 tablets placebo, oral.

Timeline

• Start date: 2026-01-04
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-12-17
• Last updated: 2026-01-14

Locations

1 site across 1 country: China